IBJNews

Investor pressure pushing drugmakers to make deals

Back to TopCommentsE-mailPrintBookmark and Share

Drugmakers eager to satisfy shareholders by boosting profit and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Tuesday's blockbuster deal involving Indianapolis-based Eli Lilly and Co. was just the latest of several that have taken place since the beginning of the year.

In that deal, Swiss drugmaker Novartis AG said it's trading its vaccine business for GlaxoSmithKline Plc's cancer drug business and selling its veterinary drug business to Lilly.

Lilly shares were down 10 cents late Wednesday morning, to $59.92 each, one day after falling 94 cents in wake of the deal's announcement.

Meanwhile on Tuesday, Canadian drugmaker Valeant Pharmaceuticals International Inc. said it teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $45 billion.

Amid easier financing and low interest rates, four smaller drugmakers also announced bids of $3 billion or more to acquire competitors since January, according to data and research firm The Mergermarket Group. The biggest is a $23 billion bid by Forest Laboratories Inc. for Actavis Inc.

The deals partly reflect a push by the pharmaceutical industry to boost sales and cut costs as drugmakers look for ways to return to the growth investors have come to expect after the bullish last two decades, when they continually churned out new blockbusters, drugs with annual sales of more than a billion dollars.

Most drugmakers have since seen revenue flatline or even dip as a tidal wave of cheaper generic competition to former blockbuster pills over the past few years wiped out billions of dollars in annual revenue. Others see the wave coming — Novartis, for instance, is awaiting generic competition to its blockbuster blood-pressure drug Diovan — and are trying to lessen the impact.

At the same time, research to develop new medicines to replace lost income is ever more difficult and expensive. Mergers and acquisitions give them additional sources of revenue and new ways to cut costs and become more efficient while they wait for drugs in their research pipeline to win approval.

Most of the spurt of mergers and acquisitions are meant to narrow the drugmaker's focus, a strategy that's in vogue now, partly due to pressure from analysts and investors. The pharmaceutical industry tends to cycle back and forth every several years between periods where most companies are divesting to focus on their core areas, or diversifying by snapping up other types of drugs or related businesses.

"Wall Street has been rewarding more-focused companies" with higher share prices, said Les Funtleyder, a consulting partner at healthcare investing firm BlueCloud Healthcare. "You see one company doing something and others feel like they have to make a strategic response."

Eric Gordon, an analyst and professor at the University of Michigan's Ross School of Business, said the industry is rearranging, with companies reducing the number of diseases they're attacking and divesting noncore businesses to others stronger in those fields.

"A few years ago, it would have been the opposite. They were acquiring things so they wouldn't be so dependent on one area" or drug, Gordon said. Then "that doesn't do the magic that's expected of it, so we divest and get focused. In 2019, we'll probably be conglomerating again."

In the short run, analysts say the deals will boost drugmakers' share prices and guarantee yet another round of layoffs in the industry. The layoffs, plus other synergies as the new assets are integrated, should boost profit margins in the midterm.

Meanwhile, patients "waiting for a cure" won't see benefits soon, but might eventually, Gordon said. That's because rejiggered companies with strong scientific teams and commitment to a particular disease area could be less likely to scrap experimental drugs in that field when they run into some bumps during patient testing. On the other hand, the companies may decide to reduce the number of experimental drugs they push through increasingly expensive stages of patient testing.

"There is that danger," Gordon warned.

ADVERTISEMENT

  • payed a premium
    The synergies that they will be saving from are lost jobs to Novartis Animal Products employees and Lilly Elanco employees. Sales duplication will be eliminated, and business functions such as accounting, finance, etc. duplications will be eliminated. Also, since most of the Novartis side is foreign based, Lilly can invest its foreign profits without any tax implications in the United States. A great deal for Lilly corporate, a less than great deal for Novartis Animal Product employees at headquarters offshore and Lilly Elanco sales offshore. The net is a combination funded by Lilly offshore dollars, no tax implications, and rank and file workers will take a hit, but not management in the executive ranks.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Hello Dear Are you tired of Seeking Loans and Mortgages,have you Been Turned down constantly By your banks and Other Financial Institutions or Micro Finance scheme. This is let you know with 100% guarantee that we Offer loans ranging from $1,000 Minimum to $1,000,000.00 Maximum at 3% interest rate per Month. We give out LOANS for developing business. a competitive edge/business expansion. email address: michealscottloan124@gmail.com We offer the following kinds of loans and many more; * Personal Loans ( Unsecured Loan) * Business Loans ( Unsecured Loan) * Consolidation Loan * Combination Loan * Home Improvement * Xmas Loans for contact to seek for loan email this email address: michealscottloan124@gmail.com Thanks

  2. My name is Mr Henry Josh and i live in the USA California and life is worth living right now for me and my family and all this is because of one man sent by GOD to help me and my family, i once had a life filled with sorrow because my first SON needed a kidney transplant and all our savings were going towards his medications and this normally leaves us with no money to pay our bills or even put enough food on our table and our rent was due and no funds to pay these bills and life felt so unfair to me and every night my wife will cry herself to sleep every night until one day, i was browsing through yahoo answers and i saw a striking advert of a man that gives out personal loans and that the offer is opened to all and i have heard so many things about internet scams but at this point of my life, i was very desperate and ready to take any risk and at the end of the day, i applied for this loan and from one step to another, i got my loan within 12 hours through bank transfer and you know, it was all like a dream and i called Mr Daniel Jones A Man who is the GOD sent lender i found and said, i have received my loan and he smiled stating that to GOD be the glory and i was so shocked as i have never ever seen anyone with such a GOD fearing and kind heart and today, i am the happiest man on earth because by GOD’S grace, my SON kidney transplant was successful and today he is healthy, i and my family are living very comfortable and happy and if you are in my former situation or in serious and legitimate need of a loan, you can reach this GOD sent lender via fidelityloanfirm@outlook.com

  3. Greetings to everyone reading this comment!!! I am Greg William by name. I am out here to recommend the effort of Mark Oscar,I was in need of a consolidation loan amount of 50,000 and as soon as I got in contact with Mark Oscar Loan Firm on Wednesday last week and on Friday last week as well I receive an alert from my bank(Royal Bank of Scotland Group) that the fund was transferred,I want everybody on this site to contact Mark Oscar now via email on how to get a loan because I got my loan from them and I am very happy,so contact them now. Oscarloanfinance@hotmail.com Thanks!!!!!!

  4. Elected officials, like Mourdock, get vested in 8 years. It takes 10 years for all other public employees, most of whom make a lot less money. So much for the promise to finish out his term.

  5. Great state treasurer and a good man!! Just curious if the folks who didn't quite understand his quote would like to tell my daughter-in-law that God didn't intend her! Mourdock's comment was correct but twisted and the article didn't mention that his opponent and the press let the impression stand that Mourdock meant that the rape was intended. Stupid people!!

ADVERTISEMENT